AKESF
Price
$13.48
Change
-$1.47 (-9.83%)
Updated
Nov 18 closing price
Capitalization
13.25B
Intraday BUY SELL Signals
NUVL
Price
$107.06
Change
+$2.82 (+2.71%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
7.78B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKESF vs NUVL

Header iconAKESF vs NUVL Comparison
Open Charts AKESF vs NUVLBanner chart's image
AKESO
Price$13.48
Change-$1.47 (-9.83%)
Volume$200
Capitalization13.25B
Nuvalent
Price$107.06
Change+$2.82 (+2.71%)
Volume$30.16K
Capitalization7.78B
AKESF vs NUVL Comparison Chart in %
AKESF
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AKESF vs. NUVL commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKESF is a Hold and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (AKESF: $13.48 vs. NUVL: $104.24)
Brand notoriety: AKESF and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKESF: 16% vs. NUVL: 224%
Market capitalization -- AKESF: $13.25B vs. NUVL: $7.78B
AKESF [@Biotechnology] is valued at $13.25B. NUVL’s [@Biotechnology] market capitalization is $7.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKESF’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • AKESF’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKESF and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKESF’s TA Score shows that 3 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • AKESF’s TA Score: 3 bullish, 4 bearish.
  • NUVL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than AKESF.

Price Growth

AKESF (@Biotechnology) experienced а -8.14% price change this week, while NUVL (@Biotechnology) price change was +8.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKESF($13.2B) has a higher market cap than NUVL($7.78B). AKESF YTD gains are higher at: 93.571 vs. NUVL (36.765).
AKESFNUVLAKESF / NUVL
Capitalization13.2B7.78B170%
EBITDAN/A-398.38M-
Gain YTD93.57136.765255%
P/E Ratio25.37N/A-
RevenueN/A0-
Total CashN/A943M-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
AKESFNUVL
RSI
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
58%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
AKESF
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CWMFX65.730.22
+0.34%
American Funds Washington Mutual 529F1
RMQHX667.81N/A
N/A
Rydex Monthly Rbl NASDAQ-100® 2x Strt H
NSIDX14.84N/A
N/A
Northern Small Cap Index
FEIQX35.07N/A
N/A
Franklin Equity Income R6
TIVFX20.28-0.07
-0.34%
American Beacon IMC Int Small Cap Inv

AKESF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKESF has been loosely correlated with INBX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AKESF jumps, then INBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKESF
1D Price
Change %
AKESF100%
+0.52%
INBX - AKESF
45%
Loosely correlated
+5.86%
SMMT - AKESF
27%
Poorly correlated
-1.55%
NUVL - AKESF
25%
Poorly correlated
+2.71%
BNTX - AKESF
23%
Poorly correlated
-1.07%
CPMV - AKESF
22%
Poorly correlated
N/A
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.71%
RVMD - NUVL
61%
Loosely correlated
-0.04%
XNCR - NUVL
60%
Loosely correlated
-1.62%
IDYA - NUVL
59%
Loosely correlated
-1.72%
XENE - NUVL
59%
Loosely correlated
+0.15%
CGON - NUVL
58%
Loosely correlated
+0.16%
More